<DOC>
	<DOCNO>NCT00499343</DOCNO>
	<brief_summary>Primary Objectives : 1 . To determine efficacy vivo purge achieve rituximab two group . 2 . To determine number apheresis procedure , total stem cell yield/kg patient body weight toxicity profile two group . Secondary Objectives : 1 . To determine degree expression various adhesion molecule 2 group correlate time engraftment neutrophil , platelet , red blood cell , efficacy stem cell mobilization purge . 2 . To determine incidence disease progression/relapse 12 month two group .</brief_summary>
	<brief_title>G-CSF Versus G-CSF Plus GM-CSF Stem Cell Mobilization NHL Patients</brief_title>
	<detailed_description>Granulocyte-colony stimulating factor ( G-CSF ) granulocyte macrophage-colony stimulating factor ( GM-CSF ) synthetic ( man-made ) version substance naturally produce body . These substance , call colony stimulating factor , help bone marrow make new white blood cell . When certain cancer medicine fight cancer cell , also affect white blood cell fight infection . To help decrease risk infection cancer medicine use , colony stimulate factor may give . Colony stimulate factor also use help bone marrow recover bone marrow transplantation stem cell transplantation . They also use increase stem cell count blood adequate number stem cell collect purpose transplantation . Before study begin , complete physical exam blood ( around 1-2 tablespoon ) urine collect routine test . You x-rays CT scan check status disease . A sample bone marrow collect test . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Your heart lung function evaluate . You electrocardiogram ( ECG - test measure electrical activity heart ) either echocardiogram multigated acquisition scan ( MUGA ) ( test measure heart function ) . You also lung function test . Women able child must negative blood urine pregnancy test . You plastic tube ( central venous catheter - CVL ) insert collarbone . The CVL leave place duration treatment . The catheter use deliver drug collection transfusion stem cell . When possible , drug need give vein give use catheter . All treatment give M. D. Anderson . First , give chemotherapy increase number stem cell blood stream . This chemotherapy include drug ifosfamide , etoposide , rituximab . You receive high dose rituximab standard care . The drug ifosfamide start Day 2 give continuous injection vein 72 hour . The drug etoposide also start Day 2 give vein 2 hour every 12 hour . Rituximab give vein 4-6 hour Days 1 8 . To help decrease risk develop side effect cause chemotherapy , give fluid vein drug call mesna . Mesna give vein 24 hour treatment ifosfamide finish . You stay hospital 4-6 day part treatment . You randomly assign ( toss coin ) one two treatment group . Participants one group receive G-CSF GM-CSF . Participants group receive G-CSF alone . After completion chemotherapy , get GM-CSF G-CSF G-CSF injection ( give skin ) twice day . These drug give help increase number white blood cell continue give adequate number stem cell collect . During time , blood collect test ( around 1 tablespoon ) least 3 time week . If doctor feel necessary , may blood collect often . Blood stem cell collect blood count return normal ( 10-16 day chemotherapy ) . The process stem cell collection take 4 hour . It may take 1-6 session collect number stem cell need transplant . The process stem cell collection call apheresis . A machine attach catheter collar bone blood withdrawn . The blood flow machine , remove stem cell blood . The blood return back catheter . The stem cell frozen store . These stem cell give back next phase treatment help blood count recover high dose chemotherapy . After enough stem cell collect , admit hospital high dose chemotherapy . You check-up visit various time next year part standard evaluation transplantation check status disease . This investigational study . All drug use study FDA approve commercially available . Up 100 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Patients histologically confirm CD20 positive Bcell nonHodgkin 's lymphoma candidate autologous stem cell transplantation . 2 . Age 70 year 3 . Platelet count &gt; 100,000 mm3 , independent transfusion support 4 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 5 . Zubrod performance status 2 less . 6 . Negative pregnancy test woman 7 . Less 10 % marrow involvement lymphoma within 4 week study enrollment define bilateral bone marrow aspiration biopsy . 8 . Should seronegative HIV , HTLV , hepatitis B surface antigen , hepatitis C antibody . 1 . Clinical radiographic evidence active CNS disease 2 . Severe concomitant medical psychiatric illness 3 . Lactating breast feeding females 4 . Less 3 week first day last chemotherapy 5 . Prior myeloablative therapy autologous bone marrow stem cell rescue 6 . Serum bilirubin &gt; 1.5 X ULN , Serum transaminases &gt; 2XULN . 7 . Serum creatinine &gt; 1.6 mg/dl 8 . History pelvic radiation 9 . Patients receive 3 prior chemotherapy regimen ( exclude radiation ) 10 . Patients receive 6 cycle fludarabine therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Etoposide</keyword>
	<keyword>G-CSF</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Isophosphamide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Leukine</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Stem Cell Collection</keyword>
</DOC>